Open AccessCancer‐associated fibroblast and M 2 macrophage markers together predict outcome in colorectal cancer patients
Author(s) -
Herrera Mercedes,
Herrera Alberto,
Domínguez Gemma,
Silva Javier,
García Vanesa,
García José M.,
Gómez Irene,
Soldevilla Beatriz,
Muñoz Concepción,
Provencio Mariano,
CamposMartin Yolanda,
García de Herreros Antonio,
Casal Ignacio,
Bonilla Félix,
Peña Cristina
Publication year - 2013
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12096
Subject(s) - colorectal cancer , malignancy , immunohistochemistry , cancer , fibroblast activation protein, alpha , medicine , pathology , cancer associated fibroblasts , tumor progression , tumor microenvironment , cancer research , oncology
Tumor epithelial cells within a tumor coexist with a complex microenvironment in which a variety of interactions between its various components determine the behavior of the primary tumors. Cancer‐associated fibroblasts ( CAF ) and M 2 macrophages, characterized by high expression of different markers, including α‐ SMA , FSP 1 and FAP , or CD 163 and DCSIGN , respectively, are involved in the malignancy of different tumors. In the present study, expression of the above markers in CAF and M 2 macrophages was analyzed using RT ‐ PCR and immunohistochemistry in the normal mucosa and tumor tissue from a cohort of 289 colorectal cancer patients. Expression of CAF and M 2 markers is associated with the clinical outcome of colorectal cancer patients. Moreover, the combination of CAF and M 2 markers identifies three groups of patients with clear differences in the progression of the disease. This combined variable could be a decisive factor in the survival of advanced‐stage patients. Taken together, these analyses demonstrate the prognostic involvement of interrelationships between DCSIGN , CD 163, α‐ SMA , FSP 1 and FAP markers in the survival of colon cancer patients.